The small molecule SI113 synergizes with mitotic spindle poisons in arresting the growth of human glioblastoma multiforme by Abbruzzese, Claudia et al.
Oncotarget1www.impactjournals.com/oncotarget
The small molecule SI113 synergizes with mitotic spindle poisons 
in arresting the growth of human glioblastoma multiforme
Claudia Abbruzzese1,*, Giada Catalogna2,*, Enzo Gallo3, Simona di Martino3, Anna 
M. Mileo4, Mariantonia Carosi3, Vincenzo Dattilo2, Silvia Schenone5, Francesca 
Musumeci5, Patrizia Lavia6, Nicola Perrotti2, Rosario Amato2 and Marco G. Paggi1
1Department of Research, Advanced Diagnostics and Technological Innovation, Unit of Cellular Networks and Therapeutic 
Targets, “Regina Elena” National Cancer Institute, IRCCS, Rome, Italy
2Department of “Scienze della Salute”, University “Magna Graecia” of Catanzaro, Catanzaro, Italy
3Department of Research, Advanced Diagnostics and Technological Innovation, Unit of Pathology, “Regina Elena” National 
Cancer Institute, IRCCS, Rome, Italy
4Department of Research, Advanced Diagnostics and Technological Innovation, Unit of Tumor Immunology and Immunotherapy, 
“Regina Elena” National Cancer Institute, IRCCS, Rome, Italy
5Department of Pharmacy, University of Genova, Genova, Italy
6Institute of Molecular Biology and Pathology (IBPM), National Research Council of Italy (CNR), c/o University “La Sapienza”, 
Rome, Italy
*These authors contributed equally to this work
Correspondence to: Marco G. Paggi, email: marco.paggi@ifo.gov.it 
Rosario Amato, email: rosario.amato@unicz.it
Keywords: Glioblastoma multiforme; SI113; SGK1; Vincristine; In vivo cancer therapy 
Received: August 09, 2017    Accepted: October 29, 2017    Published: November 18, 2017
Copyright: Abbruzzese et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
Glioblastoma multiforme (GBM) is the deadliest brain tumor. State-of-art GBM 
therapy often fails to ensure control of a disease characterized by high frequency 
of recurrences and progression. In search for novel therapeutic approaches, we 
assayed the effect of compounds from a cancer drug library on the ADF GBM cell 
line, establishing their elevated sensitivity to mitotic spindle poisons. Our previous 
work showed that the effectiveness of the spindle poison paclitaxel in inhibiting 
cancer cell growth was dependent on the expression of RANBP1, a regulatory target 
of the serine/threonine kinase SGK1. Recently, we developed the small molecule 
SI113 to inhibit SGK1 activity. Therefore, we explored the outcome of the association 
between SI113 and selected spindle poisons, finding that these drugs generated 
a synergistic cytotoxic effect in GBM cells, drastically reducing their viability and 
clonogenic capabilities in vitro, as well as inhibiting tumor growth in vivo. We also 
defined the molecular bases of such a synergistic effect.
Because SI113 displays low systemic toxicity, yet strong activity in potentiating 
the effect of radiotherapy in GBM cells, we believe that this drug could be a strong 
candidate for clinical trials, with the aim to add it to the current GBM therapeutic 
approaches.
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2017
 INTRODUCTION
Glioblastoma Multiforme (GBM), the most lethal 
primary brain tumor, presents unique challenges to therapy 
due to its location, aggressive biological behavior and 
diffuse infiltrative growth, resulting in disproportionately 
high morbidity and mortality. High-tech surgery, 
molecular characterization [1], as well as the use of novel 
targeted therapies did not change substantially GBM 
patients’ prognosis, which remains definitely dismal [2, 3].
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Due to the compelling need for novel and effective 
therapeutic approaches toward GBM, we recently 
assayed a 349-compound library of anticancer agents 
using the ADF GBM cells [4] in vitro, determining the 
strong efficacy of mitotic spindle poisons in restraining 
their growth. Our group had already shown that the 
effectiveness of paclitaxel, a drug belonging to the 
same class of antimitotic drugs, is strictly related to the 
expression of the RAN-binding protein 1 (RANBP1), 
a major RAN GTPase effector. RANBP1, in turn, is 
regulated by the serum- and glucocorticoid-regulated 
kinase 1 (SGK1), a serine/threonine kinase that plays a 
key role in cancer signal transduction [5–9].
In GBM, the PI3K/mTOR signaling pathway, 
involving both AKT and SGK1, appears frequently 
dysregulated [1]. Recently, a small molecule inhibitor, 
SI113, was demonstrated to inhibit selectively the kinase 
activity of SGK1 in vitro [10]. In addition, SI113 has 
proved valuable, alone or in combination, in restraining 
in vitro and in vivo hepatocarcinoma cell growth, with 
no apparent short-term side effects in mice [11, 12]. We 
previously assayed SI113 on three established GBM cell 
lines, where this drug was able to impact on the effect of 
radiotherapy and oxidative stress, also inducing in these 
cells an autophagic cell death [13].
With this background, we decided to explore the 
outcome of the association between SI113 and selected 
mitotic spindle poisons on GBM cell viability. We report 
that these drug associations produce indeed a synergistic 
cytotoxic effect, in vitro and in vivo.
RESULTS
Screening of a drug library
A 349-compound library was screened by assaying 
the effect of each single drug on the ADF cells [4] survival 
in vitro. Cells were incubated for 48 h in the absence or 
presence of any of the library compounds, which were 
tested at a concentration of 10 nM. Drug effect was then 
evaluated using a cell viability assay. Thirteen out of 349 
drugs were able to decrease cell viability below 20% at a 
48 h exposure time (Supplementary Figure 1). Among the 
effective drugs, we found the microtubule-destabilizing 
agent Vincristine (VCR), a naturally occurring Vinca 
alkaloid [14, 15], the microtubule-stabilizing agents 
Epothilone A (EPO-A) and Epothilone B (EPO-B) [16] 
and also Ispinesib (ISP), a highly specific inhibitor of 
the kinesin spindle protein KSP1/Eg5 [17]. As expected, 
taxanes also resulted quite effective in reducing ADF cell 
viability (see below). All mentioned drugs, albeit acting in 
specific pathways, belong to the large class of antimitotic 
drugs and ultimately share a common target process, 
i.e. mitotic spindle assembly, thus hampering mitotic 
progression at prophase/prometaphase and preventing the 
generation of two viable daughter cells [15, 18, 19].
Mitotic spindle poisons synergize with SI113 in 
restraining the growth of GBM cell lines – cell 
viability assay
RAN and RANBP1 modulate the intrinsic spindle 
stability [20, 21]. In previous work, we showed that cancer 
cells displaying increased SGK1 activity, and hence 
increased RANBP1 levels, become less sensitive to the 
effects of the microtubule-stabilizing agent paclitaxel [22]. 
Consistent with this, SGK1 down-regulation sensitizes 
cancer cells to this drug [6, 23]. Further data also point 
out the effect of the SGK1 kinase inhibitor SI113 in 
restraining in vitro and in vivo proliferation in several 
cancer cells [10, 11], including GBM cells [13]. We thus 
evaluated the effect of the treatment with SI113, VCR, 
EPO-A, EPO-B and ISP on three GBM cell lines, i.e. ADF, 
U373MG and T98G, in a cell viability assay. Titration of 
the effectiveness of these drugs determined their half-
maximal inhibitory concentration (IC50) value, assayed 
by measuring the survival of the GBM cell lines after 48 h 
of exposure (Table 1). Next, in order to highlight potential 
synergistic effects, SI113 was employed on the ADF 
cells at a concentration of 8.5 µM, corresponding to its 
IC20, i.e. the concentration able to reduce cell viability of 
20%, thus allowing an 80% survival. We tested this fixed 
concentration for SI113 in association with increasing 
doses of VCR, EPO-A, EPO-B or ISP, and assessed 
cell viability after 48 h. Using the algorithm described 
by Fransson et al. [24], we analyzed the outcome of the 
combinations SI113/VCR, SI113/EPO-A, SI113/EPO-B or 
SI113/ISP compared with that of each of the compounds 
used as single agents. Indeed, in the presence of SI113 at 
its IC20 dose, titration of VCR, EPO-A, EPO-B and ISP 
yielded a decrease in cell viability which was definitely 
attributable to a synergistic effect within an extended 
range of concentrations for all four companion drugs 
(Figure 1A–1D).
SI113 induces apoptosis and autophagic cell 
death in the ADF cells
In the experimental setting described above, S113-
dependent apoptosis was highlighted by an increased 
expression of cleaved PARP detected by Western blot. In 
particular, cleaved PARP, a cell death marker typically 
linked to DNA damage in cycling cells, was clearly 
detectable when SI113 was used alone, but was induced by 
neither EPO-A nor VCR, both of which arrest the cell cycle 
in prophase/prometaphase, thus inducing mitotic cell death. 
When cells were co-treated with the combinations SI113 
plus EPO-A or SI113 plus VCR, PARP cleaved form could 
be appreciated, albeit less intensely than with SI113 alone, 
consistent with the cell cycle inhibitory effect exerted by 
EPO-A and VCR in G2-M. In parallel, SI113-dependent 
triggering of the autophagic process was clearly reflected 
by the shift in the LC3 apparent molecular mass. Autophagy 
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Table 1: IC50 values for SI113, VCR, EPO-A, EPO-B and ISP in ADF, U373MG and T98G human GBM cell lines
Cell lines IC50 (nM)
SI113 VCR EPO-A EPO-B ISP
ADF 14482 2.01 4.53 2.12 1.81
U373MG 12773 2.68 16.96 6.00 12.02
T98G 6601 6.44 5.34 2.17 4.76
Values were determined by titrating the effect of each drug, by means of a cell viability assay, after 48 h of treatment. The data 
reported are the average of two different experiments performed in triplicate.
Figure 1: Synergistic effect of SI113 and VCR, EPO-A, EPO-B or ISP in restraining the growth of the ADF cells – cell 
viability assay. (A) Dose-response curves showing the effect of SI113 (green), VCR (blue) and VCR plus a constant 8.5 µM SI113 
concentration (red) on percent viability of ADF cells. Histograms show ADF cell viability at selected drug concentrations, as indicated, to 
highlight the effect of the association of the two drugs. Synergy is characterized by a Combination Index <0.8 and, when present, its value 
is reported in red. (B) As in panel A, except for the use of EPO-A as the companion drug. (C)  As in panel A, except for the use of EPO-B 
as the companion drug. (D) As in panel A, except for the use of ISP as the companion drug. Control values were generated by adding the 
maximum amount of solvent(s) to the cells.
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was not evident when cells were exposed to either EPO-A or 
VCR alone, whereas both drugs yielded the co-appearance 
of higher and lower molecular mass LC3 forms when used 
in combination with SI113 (Figure 2). The original blots 
that have been cropped to obtain the images in Figure 2 are 
shown in Supplementary Figure 6.
Spindle poisons, but not SI113, induce mitotic 
aberrations in ADF cells
Spindle poisons act by affecting microtubule 
functions, thus arresting mitosis and inducing functional 
perturbations culminating in mitotic cell death [25–27]. 
ADF cells were exposed to SI113, VCR and EPO-A or 
to the combination of SI113 with either mitotic spindle 
poisons as above; then fluorescence microscopy analysis 
for nuclei (Hoechst 33342, blue, left column) and 
α-tubulin (fluorescent antibody, red, central column) 
was done. Merged images are shown in the right 
column (Figure 3A). Image analysis showed large cells 
with microtubule destabilization and hyperconsensed 
chromatin, harboring multiple nuclei, micronuclei and/
or multi-lobulated nuclei, all features reflecting failed 
chromosome segregation, or mis-segregation of one or 
few chromosomes (giving rise to micronuclei), favoring 
the onset of mitotic cell death, when cells were exposed to 
VCR or EPO-A, with our without SI113.
In parallel assays, cells were stained for nuclei 
(Hoechst 33342) and γ-tubulin (fluorescent antibody, 
red) for centrosome detection. Untreated (Control) cells 
displayed one or two centrosomes, indicating cells in G1 
or G2 phase, respectively, of the cell cycle. Most of SI113-
treated cells displayed two centrosomes, indicating cells 
arrested in G2. Cells treated with VCR showed condensed 
chromatin (M-arrested), displaying often large γ-tubulin 
foci (arrow), suggestive of overduplicated, clustered 
centrosomes. Overduplicated centrosomes were also 
evident in cells treated with both SI113 and VCR (arrow) 
(Figure 3B). Supplementary Figure 2 shows the complete 
experimental set, where ADF cells were treated as 
indicated and stained for nuclei (Hoechst 33342, blue, left 
column) and γ-tubulin (fluorescent antibody, red, central 
column). Merged images are shown in the right column. 
Of note, overduplicated and clustered centrosomes were 
also evident in EPO-A- and SI113/EPO-A-treated cells.
These results indicate that mitotic aberrations were 
elicited by mitotic spindle poisons alone, as expected, and 
in combination with SI113, thus the synergistic effect in 
causing cell toxicity was apparently not ascribable to direct 
interference of SI113 with the mitotic apparatus. Here, 
SI113 more likely represents an additional impairment for 
these cells due to its indirect interference with RANBP1 
via SGK1 inhibition [6, 10].
SI113 synergizes with VCR and EPO-A in 
restraining ADF cell proliferation - clonogenic assay
At this point we wished to rely on an independent 
drug toxicity assessment. We therefore performed a 
clonogenic assay, in which ADF cells were exposed to the 
drug(s) or their respective solvent(s) for 48 h, washed, and 
allowed to grow and form colonies for the subsequent 12 d. 
Colonies were then visualized by crystal violet staining, and 
the effect of the drug(s) was evaluated via the inhibition of 
Figure 2: SI113 induces apoptosis and autophagic cell death in the ADF cell line. ADF cells were incubated for 48 h in the 
absence or presence of SI113 (8.5 µM), EPO-A (3.5 nM), VCR (0.625 nM) or the combination of SI113 and EPO-A or SI113 and VCR. 
After cell lysis, SDS-PAGE and protein transfer on a PVDF membrane, cleaved PARP and LC3 were determined by Western blot. Control 
values were generated by adding the same amount of solvent(s) to the cells. β-actin determination was performed as loading control.
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Figure 3: Spindle poisons induce mitotic aberrations in ADF cells. (A) ADF cells were incubated for 48 h in the absence or 
presence of 8.5 µM SI113, 0.625 nM VCR, 3.5 nM EPO-A or the combination of SI113 and VCR or SI113 and EPO-A. Cells were then 
stained with Hoechst 33342 to highlight nuclei (blue, left column) and α-tubulin (fluorescent antibody, red, central column). Merging is 
shown in the right column. Cells incubated in the presence of VCR or EPO-A, regardless the presence or absence of SI113, appear larger, 
with microtubule destabilization and hyperconsensed chromatin, harboring multiple nuclei, micronuclei and/or multi-lobulated nuclei. 
(B) ADF cells stained with Hoechst 33342 and γ-tubulin (merged). VCR- or SI113 plus VCR- cells, treated as above, showed condensed 
chromatin (M-arrested), displaying large γ-tubulin foci (arrows), suggestive of overduplicated, clustered centrosomes. In both panels, 
control values were generated by adding the same amount of solvent(s) to the cells.
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cell colony formation, when compared to the control. VCR 
and EPO-A doses were scaled down to the concentrations 
indicated in the Figure legend, according to the different 
experimental demands. Indeed, this experimental setting 
confirmed a highly significant decrease in cell colony 
formation in the presence of combined SI113 plus VCR 
or EPO-A compared with either drug alone. In Figure 4A 
and 4B, both representative images and histograms depict 
the scarce effect of each single treatment in reducing 
colony formation, with either SI113, or VCR or EPO-A, 
contrasting with the dramatic effect evoked by the 
combination of SI113 with the two mitotic spindle poisons.
SI113 reduces the expression of stemness genes 
in ADF cells
Aiming to identify the mechanism(s) underlying the 
reduction in clonogenic potential observed in combination 
treatments, as described above, we analyzed the effect of 
SI113, VCR, EPO-A, as well as the combination of SI113 
with both mitotic spindle poisons, on the expression 
of several stemness genes, most of them specific for 
neural cells. ADF cells were exposed to drug(s) or their 
respective solvent(s) for 48 h and then subjected to 
transcript analysis. As shown in Figure 5, treatment with 
SI113, alone or in combination with EPO-A or VCR, 
yielded a modification of mRNA expression for OCT3/4, 
NANOG, NESTIN and OLIG2, all GBM or glioma 
stemness markers [28]. Statistical significance was reached 
for NANOG, NESTIN and OLIG2 only when compared 
with Control values, as indicated by the asterisks in the 
Figure. Looking at the effect of SI113, EPO-A and VCR 
as single agents, NANOG appeared significantly down-
regulated by all three drugs and OLIG2 only by VCR, 
alone or in combination with SI113. Conversely, NESTIN 
down-regulation resulted significant only when SI113 and 
VCR were used in combination and no significant down-
regulation was observed when the values were compared 
with the effect of SI113 alone.
SI113 and VCR cooperate in restraining the 
growth of ADF xenografts in immunocompromised 
mice
On the bases of the in vitro studies described 
above, we chose to employ the ADF cells in order to 
generate xenografts for in vivo experimentations. Cells 
(2.5 × 106 cells) were implanted in the flanks of NOD/
SCID female mice for in vivo treatment with SI113, 
VCR or the combination of both. Treatment of the four 
experimental arms, control, SI113 (5.4 mg/kg), VCR 
(1.1 μg/kg, a dose deliberately below those used in the 
clinics) or SI113 plus VCR, started when the tumor 
reached the volume of about 130 mm3. Drugs (or vehicles) 
were administered five days/week and tumor growth was 
monitored every 4 days for 20 days after the beginning of 
the treatment. Mice were then sacrificed when tumors in 
any of the four groups reached the volume of 1000 mm3. 
Tumors were then excised, weighed and formalin-fixed/
paraffin-embedded (FFPE).
Under these experimental conditions, a remarkable 
reduction in tumor volume was apparent for the SI113 
plus VCR arm since day 8 of treatment. Eventually, at 
day 20, both tumor volume (Figure 6A) and tumor weight 
(Figure 6B) measurements clearly indicated a statistically 
significant delay in tumor growth in SI113-, VCR- and 
SI113 plus VCR-treated arms. Of note, the combo 
treatment arm resulted by far more effective than any of 
the single drug-treated arms.
Effect of SI113, VCR, EPO-A and SI113/VCR or 
SI113/EPO-A association on U373MG and T98G 
GBM cells
Aiming to assay the effect of SI113, VCR and 
EPO-A on other cell models, we replicated selected 
experiments using the U373MG [29] and T98G [30] GBM 
cell lines.
When cell viability assay was performed using the 
U373MG cells, synergy was found when SI113 (used at 
7.9 µM concentration, i.e. the IC20 of the drug for this 
cell line) was administered together with increasing 
VCR doses (Supplementary Figure 3A). Instead, 
co-administration of SI113 with increasing EPO-A doses 
brought to a merely additive effect (Supplementary 
Figure 3B). Similar results were obtained when the 
T98G GBM cell line was employed using SI113 (used at 
5.5 µM concentration, i.e. the IC20 of the drug for this 
cell line) plus increasing concentrations of VCR or EPO-A 
(Supplementary Figure 3C and 3D).
Clonogenic assays were then performed using 
the U373MG cells. A significant inhibition in colony 
formation was found when SI113 was administered 
together with VCR, whereas co-administration of SI113 
with EPO-A brought to a less marked, yet still statistically 
significant, effect (Supplementary Figure 4A and 4B). 
When T98G cells were employed using SI113, VCR 
produced a significant reduction of colony formation; a 
similar result was observed for the association between 
SI113 and EPO-A (Supplementary Figure 5A and 5B).
DISCUSSION
Despite optimal treatment according to Stupp et al. 
[31], the median survival of GBM patients is only 12 to 
15 months, and less than 5% of patients survive for more 
than 5 years after diagnosis [1, 3].
In search for novel therapeutic approaches, we 
recently showed that the small molecule SI113 is active in 
negative modulation of major survival processes in GBM 
cells [13]. Here, by means of a drug library screening, we 
found that the ADF cell line was quite sensitive to mitotic 
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spindle poisons, also showing that their association with 
SI113 elicited a synergistic effect in restraining GBM 
cell growth and clonogenic capability. Indeed, we report 
that direct disruption of the mitotic apparatus by VCR 
or EPO-A and, concomitantly, impairment of RANBP1 
function via SI113-dependent SGK1 inhibition [10], 
heavily restrained GBM cell growth in vitro and in vivo. 
In addition, the known effect of SI113 on the PI3K/mTOR 
signal transduction pathway - SI113 being an inhibitor of 
the SGK1 kinase activity [10] - may play a further role 
in impeding GBM cell growth and survival. The reason 
underlying the noticeable in vitro and in vivo GBM cell 
impairment described in our results can be thus attributed 
to the combination of these effects.
A key point in GBM patients’ treatment is the drug 
permeability through the Blood-Brain Barrier (BBB), 
Figure 4: Synergistic effect of SI113 plus VCR, and SI113 plus EPO-A in restraining the growth of the ADF cells 
– Clonogenic Assay. (A) ADF cells were exposed to solvent(s) (Control), 8.5 µM SI113, 0.312 nM VCR or their association for 
48 h and then allowed to grow and form colonies for the subsequent 12 d. Cell colonies, after staining with crystal violet (upper panels), 
were counted and the values reported as percent colony number in the histogram (lower panel). Statistical significance is also indicated 
(*significance vs. Control; ^significance vs. SI113; §significance vs. VCR). (B) As in panel A, except for the use of 0.5 nM EPO-A as the 
companion drug. Statistical significance is also indicated (*significance vs. Control; ^significance vs. SI113; §significance vs. EPO-A).
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which may represent an obstacle to drug distribution in 
the CNS structures. Usually, BBB appears damaged in 
high-grade gliomas, due to the disruption of the normal 
cerebral vascular architecture and to tumor-induced neo-
angiogenesis. While SI113 is predicted to pass the BBB 
[13], concerns are raised for some spindle-targeting drugs, 
e.g. VCR and paclitaxel [15], whereas epothilones are 
demonstrated to pass the BBB [15, 32]. Nevertheless, in 
spite of its poor permeability through an intact BBB, VCR 
along with procarbazine and lomustine (CCNU), i.e. the 
PCV regimen, is employed in some CNS tumors [33]. In 
our in vivo studies we have coupled SI113 with VCR, also 
considering that the latter belongs to the WHO Model List 
of Essential Medicines (http://www.who.int/medicines/
publications/essentialmedicines/en/), being considered 
an effective and widely employed drug. In addition, 
VCR treatment has recently been reported to trigger an 
immune response [34]. Considering that a reduced VCR 
penetration in normal brain could be circumvented in 
several effective ways [35], our results represent a proof-
of-concept regarding the synergy between SI113 and VCR 
in impeding cancer growth.
On the whole, the results reported here outline 
a clear-cut effect of SI113, alone or in association with 
mitotic spindle poisons, on GBM vital processes by 
inducing apoptosis and autophagic cell death. The effects 
of the mitotic spindle poisons appear instead confined to 
an induction of cell death by mitotic arrest. Thus, SI113 
synergizes with VCR in potently inhibiting proliferation 
of ADF cells in vitro and in vivo and also reducing cell 
clonogenicity. Specifically, the effects of these drugs, as 
described here, are of potential relevance when envisaging 
novel combination therapeutic strategies.
State-of-art first line treatment of newly diagnosed 
GBM patients [31] (maximal surgical resection followed 
by radiotherapy and chemotherapy with temozolomide) 
Figure 5: SI113 reduces the expression of stemness genes in ADF cells. ADF cells were incubated for 48 h in the presence of 
solvent(s) (Control), 8.5 µM SI113, 3.5 nM EPO-A, 0.625 nM VCR, or a combination of them, as indicated. After nucleic acid extraction, 
quantitative PCR for OCT3/4, NANOG, NESTIN and OLIG2 mRNA expression was performed. Results, normalized against GAPDH 
expression, are represented as histograms and the statistical significance toward Control, when present, is reported on each single column.
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produces only minor benefits on patients’ survival time. 
Recent studies suggest that distinct molecular subtypes 
exist within the broader pathologic diagnosis of GBM, 
and strengthen the notion that responses to specific 
treatments vary based on the molecular subtype [36, 37]. 
The intrinsic GBM heterogeneity [38, 39] remains a real 
obstacle for complete eradication of this disease, where 
tumor recurrence arises in the majority of the patients 
and no standard of care is presently established for 
recurrent or progressive GBM. In this scenario, disease 
relapses driven by cells resistant toward previous - also 
precision medicine-driven - approaches is almost the rule. 
This could possibly be faced using therapeutic strategies 
designed to hit general cancer cell survival pathways, 
as both SI113 and mitotic spindle poisons do. The use 
of these drugs might be of great help also in providing 
a more incisive first-line treatment, when associated with 
the GBM standard therapeutic approach.
Finally, taking into account that SI113 potentiates 
the effects of radiotherapy in GBM cells [13], this drug 
can be considered as a strong candidate for GBM therapy 
in a clinical setting. Thus, we feel that all these elements 
converge to support the idea of a Phase 1 clinical trial for 
SI113 safety and dosage assessments.
MATERIALS AND METHODS
GBM cell lines
ADF human GBM cells [4] were a gift from Dr. 
W. Malorni (Istituto Superiore di Sanità, Rome, Italy). 
U373MG and T98G GBM cells were provided by Dr. 
C. Leonetti (“Regina Elena” National Cancer Institute, 
Rome, Italy). All cells were Mycoplasma-free and were 
used for a maximum of 20 passages after thawing. Cells 
were cultured at 37°C, in a humidified atmosphere of 5% 
CO2 and 95% air, in DMEM (Life Technologies, Inc., 
Grand Island, NY), supplemented with 10% fetal bovine 
serum plus 1% penicillin-streptomycin.
Anti-Cancer-Compound Library, SI113 and Cell 
Viability
We used the “Anti-cancer Compound Library” 
(L3000, Selleckchem Inc., Houston, TX) consisting of 
349 compounds all in use or under clinical trial. After 
the library screenings, VCR was purchased from Pfizer 
Inc. (New York, NY) as a 1 mg/ml solution, while EPO-A 
was purchased from Sigma-Aldrich, St. Louis, MO and 
dissolved in DMSO at a 100 µM concentration. Data for 
each single compound were reported as percent inhibition 
toward solvent-treated cells (100%).
SI113 was synthesized as previously reported [40]. 
The drug was diluted in DMSO at a 50 mM concentration.
Cell viability assays
For drug library screening and toxicity assays, cells 
were seeded in 96-well plates at 5 × 103 cells/well and 
successively exposed to the drugs (or their solvent) for 
48 h. The assay was performed by means of the CellTiter-
Glo Luminescent Cell Viability Assay (Promega KK, 
Figure 6:  SI113 synergizes with VCR in restraining the growth of ADF xenografts in immunocompromised mice. 
ADF cells (2.5 × 106 cells) were implanted in the flanks of NOD/SCID female mice. When tumors reached the volume of about 130 mm3, 
mice were divided into four arms, i.e. Control, SI113, VCR or SI113 plus VCR for the in vivo treatment. Drugs (or their solvents in the 
Control arm) were administered five days/week, and tumor growth was monitored every 4 days for 20 days after the beginning of the 
treatment. (A) The graph shows the curves for tumor growth for control and animals treated with SI113, VCR or their association. Statistical 
analysis was done using the Student’s two-tailed t test (** = P < 0.01). Data are expressed in mm3 ± Standard Error (SE). (B) At day 
20 from the beginning of the treatment, mice were sacrificed and tumors were excised and weighed. The histogram represents tumor weight 
for each experimental arm expressed in g ± SE. In this panel, statistical analysis among groups was done using the One-way ANOVA test 
followed by the Tukey’s Multiple Comparison Test. Statistical significance is also indicated (*significance vs. Control; ^significance vs. 
SI113; §significance vs. VCR).
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Tokyo, Japan), employing all the 349 compounds at 
the concentrations of 10 nM. For selected drugs (VCR, 
EPO-A, EPO-B, ISP and SI113), a dose-response curve 
was accomplished for IC50 evaluation. Cell viability 
was determined by means of a GLOMAX 96 Microplate 
Luminometer (Promega).
Colony-forming assays
Cells were plated at 100–200 cells/well in 6-well 
plates. The following day vehicle, SI113, VCR, EPO-A or 
a combination of two compounds (as indicated) was added 
and the culture was incubated for 48 h. After washing, 
cells were incubated for 12 d and then stained with a 5% 
crystal violet solution in order to count the colony number.
Immunoblot analysis
Cells were treated as described [6] and probed with 
anti-cleaved PARP (Asp214) PAb (1:500, Cell Signaling 
Technology, Inc. Danvers, MA); anti-LC3 PAb (1:400, 
MBL International, Woburn, MA); anti-β-actin MAb 
(1:10000, MP Biomedicals, Aurora, OH). 
Immunofluorescence
ADF cells were plated in 6-well plates at a density 
of 1 × 104 cells per well on glass cover slips. After the 
treatments, cells were fixed in a 4% paraformaldehyde 
solution and permeabilized with 0.1% Triton-X100 in 
PBS at room temperature. After blocking in 1% BSA in 
PBS, cells were incubated with α-tubulin monoclonal 
antibody (1:100, Calbiochem, San Diego, CA) and 
then with an Alexa 594-conjugated secondary antibody 
(Life Technologies). Another set of ADF cells, after 
treatments, was fixed in ice-cold methanol, blocked 
and immunostained for mitotic center with a γ-tubulin 
monoclonal antibody (Santa Cruz Biotechnology) at a 
1:200 dilution. Nuclear counterstaining was performed 
by means of Hoechst 33342. After extensive washing, 
immunostaining was visualized using an Olympus BX53 
Fluorescence Microscope (Olympus Corporation of the 
Americas, Center Valley, PA) equipped with a Jenoptic 
ProgRes MF (Jena, Germany) digital camera. Images were 
then processed using the NIS-Elements HC 4.2 software 
(Nikon Instruments, Campo Bisenzio, Florence, Italy).
Real-time PCR
Total RNA was extracted from ADF cells using 
the MasterPure RNA Purification Kit (Epicentre 
Biotechnologies, Madison, WI). RNA was reverse-
transcribed into cDNA using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems Inc., 
Foster City, CA) and subject to 7500 Fast System Real 
Time PCR (Bio-Rad Laboratories, Hercules, CA) with 
PowerUp SYBR Green Master Mix (Applied Biosystems). 
Primers were designed for different targets as specified 
below; primers designed for GAPDH were applied as 
internal controls:
OCT3/4 [41] Sense: 5ʹ-TGGAGAAGGAGAA 
GCTGGAGCAAAA-3ʹ
Antisense:  5ʹ-GGCAGATGGTCGTTTGGCTGA 
ATA-3ʹ
NANOG [42] Sense: 5ʹ-CAAAGGCAAACAAC 
CCACTT-3ʹ
Antisense: 5ʹ-ATTGTTCCAGGTCTGGTTGC-3ʹ




OLIG2 [44] Sense: 5ʹ-CCAGAGCCCGATGAC 
CTTTTT-3ʹ
Antisense: 5ʹ-CACTGCCTCCTAGCTTGTCC-3ʹ
These primers are reported to be extremely specific 
and to not amplify genomic DNA. PCR conditions were: 
50°C for 2 min, 95°C for 2 min, followed by 40 cycles 
of 95°C/15 s, annealing at 56°C/30 s and 72°C/30 s. All 
reactions were performed in triplicate using RNA from 
two different sets of samples.
Mouse xenograft model and tumor growth delay 
experiments
Four-week-old female NOD/SCID mice (Harlan, 
Indianapolis, IN) were maintained under pathogen-
free conditions and given food and water ad libitum. 
Experiments were carried out in accordance with the 
Catanzaro University Institutional Animal Care and Use 
Committee guidelines, using an approved protocol. At 
6 weeks of age, mice were subcutaneously injected with 
2.5 × 106 ADF cells suspended in 200 µl of a 1:1 solution 
containing DMEM without serum plus Matrigel solution 
(BD Biosciences, San José, CA) in the dorsal posterior-
lateral right region. Tumors were allowed to grow for 
four days, then mice were randomly assigned to four 
groups and treated with vehicle alone (DMSO, control 
group, six animals), SI113 (eight animals), VCR (eight 
animals) or SI113 plus VCR (eight animals) for five days/
week. Tumors were measured every four days by caliper 
in two perpendicular diameters (a = smaller diameter; 
b = larger diameter) and the tumor volume was calculated 
by using the modified ellipsoid formula 1/2(Length × 
Width2). Mice, under general anesthesia, were sacrificed 
by vertebral dislocation.
Statistical analysis
Unless otherwise specified, all tests were done in 
triplicate and experiments performed at least three times. 
Results are expressed as a mean ± Standard Error (SE). 
Differences between groups were analyzed using the 
One-way ANOVA test followed by the Tukey’s Multiple 
Comparison Test (GraphPad Prism v5). Symbols (*; ^; §) 
Oncotarget11www.impactjournals.com/oncotarget
denote statistical significance as indicated in the Figure 
legends (one symbol <0.05; two symbols <0.01; three 
symbols <0.001).
In Figure 6A, differences between groups were 
analyzed using the Student’s two-tailed t test (GraphPad 
Prism v5). Asterisks denote statistical significance.
The assessment of synergy between two drugs was 
done using the algorithm described by Fransson et al. [24]. 
Synergy is characterized by a Combination Index <0.8, 
while a Combination Index between 0.8 and 1.2 indicates an 
additive effect; values >1.2 indicate an antagonistic effect.
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